Shasqi Appoints Steve Abella, M.D., as Chief Medical Officer and Scott Wieland, Ph.D., MBA, as SVP of Clinical Development

Shasqi Appoints Steve Abella, M.D., as Chief Medical Officer and Scott Wieland, Ph.D., MBA, as SVP of Clinical Development

May 24, 2022 by Business Wire Health: Oncology News

Key Facts

  • Prior to that, he served as Senior Director at Gilead Sciences where he led the non-Hodgkin’s lymphoma and leukemia drug development efforts and served as a core member of the oncology senior leadership team.
  • Before he joined the biopharmaceutical industry, he spent 15 years in academic oncology, serving as a Professor of Pediatric, Oncology, and Medicine at the Barbara Ann Karmanos Cancer Institute where he focused on stem cell transplantation and oncology clinical trials.
  • Over the course of his career, Scott has served in a variety of roles and responsibilities, most recently as Executive Vice President of Development at Nanobiotix, a nanomedicine company based in Paris, France.
  • Shasqi’s CAPAC Platform is highly modular and can be applied to a broad range of cancer drugs that are otherwise limited by toxicity, enabling the exploration of therapeutic biology in ways that were not previously possible.

Click To Read Full Article

GEOGRAPHY
PERSON
ORGANIZATION
WORK OF ART
PRODUCT
MISCELLANEOUS

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?